Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001295759 | SCV001484704 | likely pathogenic | Walker-Warburg congenital muscular dystrophy | 2023-11-05 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 69 of the FKRP protein (p.Ser69Pro). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FKRP-related conditions. ClinVar contains an entry for this variant (Variation ID: 999725). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FKRP protein function with a positive predictive value of 95%. This variant disrupts the p.Ser69 amino acid residue in FKRP. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27142102, 27439679). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Ambry Genetics | RCV002418887 | SCV002724772 | uncertain significance | Cardiovascular phenotype | 2019-03-20 | criteria provided, single submitter | clinical testing | The p.S69P variant (also known as c.205T>C), located in coding exon 1 of the FKRP gene, results from a T to C substitution at nucleotide position 205. The serine at codon 69 is replaced by proline, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002493553 | SCV002779789 | uncertain significance | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1; Muscular dystrophy-dystroglycanopathy type B5; Autosomal recessive limb-girdle muscular dystrophy type 2I; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5 | 2021-09-23 | criteria provided, single submitter | clinical testing | |
Duke University Health System Sequencing Clinic, |
RCV001830129 | SCV003919048 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2I | 2023-04-20 | criteria provided, single submitter | research | |
Natera, |
RCV001830129 | SCV002088938 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2I | 2021-10-04 | no assertion criteria provided | clinical testing |